Investor Presentation H1 2023 slide image

Investor Presentation H1 2023

61 Investor presentation First six months of 2023 Novo NordiskⓇ Large opportunity for activating more people with obesity to seek treatment and increasing the number of prescribers ONCE-WEEKLY wegovy® semaglutide injection 2.4 mg 77% WegovyⓇ patient characteristics in the US 30% 81% 37.5 of patients new to anti- obesity medication¹ of patients are female Average BMI of patients have ≥3 co- morbidities Of the people with overweight or obesity in the US, almost 90% have a weight-related comorbidity BMI (million of people) 27-30 (43) 30-35 (52) 35-40 (25) ≥40 (20) Total (140) 140 No obesity-related comorbidity² 7 (16%) 6 (12%) 2 (9%) 2 (8%) 17 (12%) million people with a BMI > 27 Any obesity-related comorbidity 36 (84%) 46 (88%) 23 (92%) 18 (90%) 123 (88%) Hereof metabolic syndrome³ 21 (48%) 26 (50%) 14 (56%) 12 (61%) 72 (52%) Hereof ASCVD 4 (8%) 5 (10%) 3 (10%) 2 (10%) 13 (9%) ¹Naïve to AOM treatment is based on total info in the database and not restricted to 12 months prior WegovyⓇ prescription 2 Individuals without any of the following obesity related conditions: T2DM, Pre-diabetes, NASH, NAFLD, obstructive sleep apnea, osteoarthritis, PCOS, ASCVD, Heart failure, asthma, urinary incontinence, hypertension, chronic kidney disease stg. 3 or 4, musculoskeletal pain, dyslipideamia, metabolic syndrome; 3 Metabolic syndrome defined as two or more of dyslipidaemia; hypertension; prediabetes OR type II diabetes Source: Novo Nordisk real world research; National Health And Examination Survey (NHANES) cycles 2015-2016 and 2017-2018. BMI; Body mass index; ASCVD: Atherosclerotic cardiovascular disease
View entire presentation